REGENERON PHARMACEUTICALS INC. - COMMON STOCK
573.45
04-April-25 15:45:00
15 minutes delayed
Stocks
-37.19
-6.09%
Today's range
572.00 - 612.99
ISIN
N/A
Source
NASDAQ
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
04 Apr 2025 08:46:04 By NetDania Notify
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
03 Apr 2025 15:08:52 By NetDania Notify
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
02 Apr 2025 08:45:07 By NetDania Notify
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
01 Apr 2025 13:45:14 By NetDania Notify
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
31 Mar 2025 08:50:37 By NetDania Notify
-
28 Mar 2025 01:00:14 By Nasdaq GlobeNewswire
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
26 Mar 2025 08:46:28 By NetDania Notify
-
25 Mar 2025 15:05:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
25 Mar 2025 13:10:05 By NetDania Notify
-
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
08 Mar 2025 12:00:00 By Nasdaq GlobeNewswire
-
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
28 Feb 2025 06:00:02 By Nasdaq GlobeNewswire
-
26 Feb 2025 06:00:19 By Nasdaq GlobeNewswire
-
24 Feb 2025 14:00:04 By Nasdaq GlobeNewswire
-
17 Feb 2025 23:59:00 By Nasdaq GlobeNewswire
-
Regeneron Announces Investor Conference Presentations
11 Feb 2025 15:05:00 By Nasdaq GlobeNewswire
-
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
11 Feb 2025 06:00:39 By Nasdaq GlobeNewswire
-
08 Feb 2025 16:40:16 By Nasdaq GlobeNewswire
-
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
04 Feb 2025 08:45:06 By NetDania Notify
- <<
- <
- 1
- >